RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud Investigation – Contact BFA Law if You Lost Money

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [4]. - A further revenue forecast cut on July 8, 2025, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [5].